Table 4.

Frequency of infants meeting the primary outcome measure of seroprotection^* against ≥5 vaccine serotypes at 8 weeks of life.

Group	N	Frequency per group (95% CI)	Groups compared	% Difference (95% CI)	P value#
Vaccine PCV-10	108	19% (12%, 27%)	PCV-23 vs. PCV-10	5% (−7%, 16%)	0.5
Vaccine PPV-23	104	23% (15%, 32%)	PCV-10 vs. Placebo	18% (10%, 26%)	<0.0001
Placebo	109	1% (0%, 55)	PCV-23 vs. Placebo	22% (14%, 31%)	<0.0001

^*Seroprotection was defined by antibody concentrations≥ 0.35 μg/ml.

^#Fisher’s Exact Test.